Sugi Predict

Sugi Predict / Compounds / SCHEMBL1269918

SCHEMBL1269918

SCHEMBL1269918

CO[C@@H]1CN[C@H](C(=O)O)C1

nearest known ligand 0.52

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ CYP2D6 P10635 3/20 0.52
▸ CYP1A2 P05177 2/20 0.52
▸ ALOX15 P16050 2/20 0.52
▸ CYP2C19 P33261 2/20 0.52
▸ SLC1A3 P43003 1/20 0.52
▸ SLC1A2 P43004 1/20 0.52
▸ SLC1A1 P43005 1/20 0.52
▸ ARG1 P05089 1/20 0.44
▸ CTSC P53634 1/20 0.43
▸ LMNA P02545 2/20 0.41
▸ BLM P54132 2/20 0.41
▸ TSHR P16473 1/20 0.41
▸ RAB9A P51151 1/20 0.41
▸ MEN1 O00255 1/20 0.41
▸ THRB P10828 1/20 0.41
▸ PMP22 Q01453 1/20 0.41
▸ KMT2A Q03164 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL689400 1.00 CYP2D6 (0.52) CYP2D6CYP1A2ALOX15CYP2C19SLC1A3
SCHEMBL5636193 1.00 CYP2D6 (0.52) CYP2D6CYP1A2ALOX15CYP2C19SLC1A3
SCHEMBL1270327 1.00 CYP2D6 (0.52) CYP2D6CYP1A2ALOX15CYP2C19SLC1A3
SCHEMBL7279796 1.00 CYP2D6 (0.52) CYP2D6CYP1A2ALOX15CYP2C19SLC1A3
SCHEMBL7361978 1.00 CYP2D6 (0.52) CYP2D6CYP1A2ALOX15CYP2C19SLC1A3
SCHEMBL7338717 1.00 CYP2D6 (0.52) CYP2D6CYP1A2ALOX15CYP2C19SLC1A3
SCHEMBL7338708 1.00 CYP2D6 (0.52) CYP2D6CYP1A2ALOX15CYP2C19SLC1A3
Hydrochloric Acid SCHEMBL1302881 0.98 CYP2D6 (0.50) CYP2D6CYP1A2ALOX15CYP2C19SLC1A3
Hydrochloric Acid SCHEMBL1268656 0.98 CYP2D6 (0.50) CYP2D6CYP1A2ALOX15CYP2C19SLC1A3
Hydrochloric Acid SCHEMBL20446559 0.98 CYP2D6 (0.50) CYP2D6CYP1A2ALOX15CYP2C19SLC1A3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 96 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11939314-B2 Quinolin-2-one derivatives MERCK PATENT GMBH (DE) 2024-03-26 — — US claimed
US-20230028687-A1 QUINOLIN-2-ONE DERIVATIVES MERCK PATENT GMBH (DE) 2023-01-26 — — US claimed
US-11174241-B2 Quinolin-2-one derivatives MERCK PATENT GMBH (DE) 2021-11-16 — — US claimed
CN-108473485-B Quinolin-2-one derivatives 默克专利股份公司 2021-11-02 — — CN claimed
US-20200190054-A1 QUINOLIN-2-ONE DERIVATIVES MERCK PATENT GMBH (DE) 2020-06-18 — — US claimed
US-20200190055-A1 QUINOLIN-2-ONE DERIVATIVES MERCK PATENT GMBH (DE) 2020-06-18 — — US claimed
US-10669251-B2 Quinolin-2-one derivatives MERCK PATENT GMBH (DE) 2020-06-02 — — US claimed
US-20190023685-A1 QUINOLIN-2-ONE DERIVATIVES MERCK PATENT GMBH (DE) 2019-01-24 — — US claimed
EP-3402792-A1 QUINOLIN-2-ONE DERIVATIVES Merck Patent GmbH (DE) 2018-11-21 — — EP claimed
WO-2017121444-A1 QUINOLIN-2-ONE DERIVATIVES MERCK PATENT GMBH (DE) 2017-07-20 — — WO claimed
US-20120302747-A1 PYRROLOTRIAZINE KINASE INHIBITORS BRISTOL-MYERS SQUIBB COMPANY 2012-11-29 — — US claimed
US-20110124623-A1 PYRROLOTRIAZINE KINASE INHIBITORS BRISTOL-MYERS SQUIBB COMPANY 2011-05-26 — — US claimed
US-12479856-B2 Pharmaceutical compounds for the treatment of complement mediated disorders ACHILLION PHARMACEUTICALS, INC. (US) 2025-11-25 — — US disclosed
EP-4603105-A1 PHARMACEUTICAL COMPOSITION CONTAINING CYCLIC COMPOUND HAVING SELECTIVE KRAS INHIBITORY EFFECT AGAINST HRAS AND NRAS CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2025-08-20 — — EP disclosed
EP-4592308-A1 CYCLIC COMPOUND HAVING SELECTIVE KRAS INHIBITORY EFFECT ON HRAS AND NRAS CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2025-07-30 — — EP disclosed
WO-2025132542-A1 MACROCYCLIC OREXIN AGONISTS IDORSIA PHARMACEUTICALS LTD (CH) 2025-06-26 — — WO disclosed
EP-0618809-A1 BRADYKININ TYPE PEPTIDES SCIOS NOVA INC. (US) 1994-10-12 — — EP disclosed
EP-0618809-A4 BRADYKININ TYPE PEPTIDES. SCIOS NOVA INC (US) 1994-07-28 — — EP disclosed
WO-1992018155-A1 BRADYKININ TYPE PEPTIDES NOVA TECHNOLOGY LIMITED PARTNERSHIP (US) 1992-10-29 — — WO disclosed
US-4316906-A HYPOTENSIVE AGENTS E. R. SQUIBB & SONS, INC. (US) 1982-02-23 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11174241-B2 Quinolin-2-one derivatives KIT, CDK2, CDK1 CYP2D6 1404/4885CYP1A2 1340/4885ALOX15 4882/4885
US-20190023685-A1 QUINOLIN-2-ONE DERIVATIVES KIT, CDK2, CDK1 CYP2D6 1404/4885CYP1A2 1340/4885ALOX15 4882/4885
US-20200190054-A1 QUINOLIN-2-ONE DERIVATIVES KIT, CDK2, CDK1 CYP2D6 1404/4885CYP1A2 1340/4885ALOX15 4882/4885
US-12479856-B2 Pharmaceutical compounds for the treatment of complement mediated disorders C5, CFH, C1QBP CYP2D6 710/4885CYP1A2 1838/4885ALOX15 201/4885
US-11939314-B2 Quinolin-2-one derivatives KIT, CDK2, CDK1 CYP2D6 1404/4885CYP1A2 1340/4885ALOX15 4882/4885
US-20230028687-A1 QUINOLIN-2-ONE DERIVATIVES KIT, CDK2, CDK1 CYP2D6 1404/4885CYP1A2 1340/4885ALOX15 4882/4885
US-20110124623-A1 PYRROLOTRIAZINE KINASE INHIBITORS STK25, STK17A, STK35 CYP2D6 2602/4885CYP1A2 1518/4885ALOX15 3031/4885
US-20200190055-A1 QUINOLIN-2-ONE DERIVATIVES KIT, CDK2, CDK1 CYP2D6 1404/4885CYP1A2 1340/4885ALOX15 4882/4885
US-20120302747-A1 PYRROLOTRIAZINE KINASE INHIBITORS STK25, STK17A, STK35 CYP2D6 2602/4885CYP1A2 1518/4885ALOX15 3031/4885
US-10669251-B2 Quinolin-2-one derivatives KIT, CDK2, CDK1 CYP2D6 1404/4885CYP1A2 1340/4885ALOX15 4882/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.